Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
Title:
Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
Author:
Tamada, Satoshi Kondoh, Chihiro Matsubara, Nobuaki Mizuno, Ryuichi Kimura, Go Anai, Satoshi Tomita, Yoshihiko Oyama, Masafumi Masumori, Naoya Kojima, Takahiro Matsumoto, Hiroaki Chen, Mei Li, Mengran Matsuda, Kenji Tanaka, Yoshinobu Rini, Brian I. Uemura, Hirotsugu